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Abstract
Background Poor performance in the 5-chair stand test (5-CST) indicates reduced lower limb muscle strength. The 5-CST has
been recommended for use in the initial assessment of sarcopenia, the accelerated loss of muscle strength and mass. In order
to facilitate the use of the 5-CST in sarcopenia assessment, our aims were to (i) describe the prevalence and factors associated
with poor performance in the 5-CST, (ii) examine the relationship between the 5-CST and gait speed, and (iii) propose a pro-
tocol for using the 5-CST.
Methods The population-based study Cognitive Function and Ageing Study II recruited people aged 65 years and over from
defined geographical localities in Cambridgeshire, Newcastle, and Nottingham. The study collected data for assessment of
functional ability during home visits, including the 5-CST and gait speed. We used multinomial logistic regression to assess
the associations between factors including the SARC-F questionnaire and the category of 5-CST performance: fast (<12 s), in-
termediate (12–15 s), slow (>15 s), or unable, with slow/unable classed as poor performance. We reviewed previous studies
on the protocol used to carry out the 5-CST.
Results A total of 7190 participants aged 65+ from the three diverse localities of Cognitive Function and Ageing Study II were
included (54.1% female). The proportion of those with poor performance in the 5-CST increased with age, from 34.3% at age
65–69 to 89.7% at age 90+. Factors independently associated with poor performance included positive responses to the
SARC-F questionnaire, physical inactivity, depression, impaired cognition, and multimorbidity (all P < 0.005). Most people
with poor performance also had slow gait speed (57.8%) or were unable to complete the gait speed test (18.4%). We
found variation in the 5-CST protocol used, for example, timing until a participant stood up for the fifth time or until they
sat down afterwards.
Conclusions Poor performance in the 5-CST is increasingly common with age and is associated with a cluster of other factors
that characterize risk for poor ageing such as physical inactivity, impaired cognition, and multimorbidity. We recommend a low
threshold for performing the 5-CST in clinical settings and provide a protocol for its use.
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The5-chair stand test (5-CST) is ameasureof the strengthof the
lower limb muscles and involves a participant being asked to
stand up from a chair and sit back down as quickly as possible
five times.1 The 5-CST has been included in cohort studies
where poor performance has been linked to subsequent
disability,2,3 falls,4 fractures,5 and mortality.2,6 The 5-CST has
also been evaluated in a range of different clinical settings.
These include as an outcome measure following hip and knee
replacement,7 in the care of patients with chronic obstructive
pulmonary disease8,9 and following discharge from intensive
care.10 Across these settings, there is evidence that the 5-CST
is reliable and that it is a valid measure of lower limb strength.
These characteristics have led to the 5-CST being recom-
mended for use in the initial assessment of sarcopenia, the ac-
celerated loss of muscle strength and mass. The European
Working Group on Sarcopenia in Older People 2 (EWGSOP2)
consensus definition11 advised that the 5-CST or handgrip tests
should be used to identify thosewith lowmuscle strength: if ei-
ther are present, this is a basis on which to investigate causes
and begin treatment. Clinically relevant questions regarding
the 5-CST arising from the EWGSOP2 definition include an un-
derstanding of which groups are likely to have poor perfor-
mance, the relationship with other components of the
EWGSOP2 definition, and guidance on the protocol to use.
The Cognitive Function and Ageing Studies are a suite of
population-based studies in different geographical localities,
recruited through general practice with population represen-
tativeness known and including care home settings. Their
aims have been to integrate physical, mental, and cognitive
domains to describe contemporary populations, including
frailty and dementia. In the most recent generational study
in Cambridgeshire, Newcastle, and Nottingham, the Cognitive
Function and Ageing Study II (CFAS II) incorporated the 5-CST
and gait speed of a large sample of community-dwelling older
people. Here, we draw on data from CFAS II to describe the
prevalence and factors associated with poor performance in
the 5-CST and to examine the relationship between the
5-CST and gait speed. We used our findings and a literature
review to propose a protocol for using the 5-CST.
Methods
Participants and ethical approval
The study design for CFAS II has been described in detail
previously.12 In brief, people aged 65 years and above living
in three geographic areas in England (Newcastle, Nottingham,
and Cambridgeshire) were recruited from general practi-
tioner lists including those residents in care settings. The
fieldwork for the first wave, as used in the present study,
was carried out between 2008 and 2011, with participants
visited at home by a trained researcher who completed a de-
tailed questionnaire covering sociodemographic information,
social engagement, activities of daily living, mental and phys-
ical health conditions, medication and cognitive measures,
along with physical and cognitive assessments. Ethical ap-
proval was granted by the Cambridgeshire 4 Research Ethics
Committee as well as relevant local research ethics commit-
tees. Study assessments were carried out only after written
informed consent was obtained, with consent sought from
a consultee if a participant lacked capacity to consent.
Assessment of chair stand test and gait speed
For the 5-CST, a firm straight back chair that was available in
the participant’s home such as a dining chair was used. The
height of the chair used therefore varied. Each participant
was asked if they would feel safe to sit on a firm straight
backed chair with their feet on the floor and their arms
folded across their chest, before standing up without using
their arms. Those participants who completed a single chair
stand without using their arms were then asked if they would
feel safe to repeat the procedure but standing up five times
as quickly as possible. The time taken to complete five rises
was recorded, timed from when they were seated and asked
to start until when they had stood up straight for the fifth
time. The researcher recorded a reason in the event a partic-
ipant felt safe to attempt but did not complete the 5-CST.
We grouped participants into the following 5-CST catego-
ries: fast (quicker than 12 s, as previously found to distinguish
those not experiencing two or more falls in a 12 month pe-
riod from those who did4), intermediate (12–15 s), slow
(greater than 15 s, as per the EWGSOP2 guidance,2,11) and
unable (grouped separately because of the associations with
adverse health outcomes,5,13 including those who were not
usually independently mobile indoors and those who did
not feel safe to attempt the test). Going forward, we refer
to participants with a slow time or those who were unable
as having poor performance in the 5-CST.
For the gait speed test, the researcher marked out a 2.4 m
course and asked the participant to walk along it at their
usual speed, using a walking aid if they felt more comfortable
to do so. The researcher timed from when the participant be-
gan walking to when one of their feet first crossed the line at
the end. The walk was performed twice, and we used the
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average of the two times to calculate their gait speed. The re-
searcher recorded a reason in the event a participant felt safe
to attempt but did not complete the gait speed test. We cat-
egorized participants into the following gait speed outcomes:
fast (≥1 m/s, as per an earlier study14), intermediate (>0.8
and <1 m/s), slow (≤0.8 m/s, as per the EWGSOP2
guidance),11 and unable (including those who were not usu-
ally independently mobile indoors).
Assessment of SARC-F score and other
characteristics
The SARC-F questionnaire is recommended as a screening
tool for sarcopenia in the EWGSOP2 definition.11 It has five
components, comprising difficulty in walking across a room,
number of falls in the last year, strength (difficulty with lifting
or carrying a 10 lb weight), difficulty with chair or bed trans-
fers, and difficulty with climbing stairs. Each is scored 0–2 in
order of increasing difficulty and a score of 4 or more sug-
gesting the presence of sarcopenia.15 We derived a SARC-F
score from CFAS II as described in Supporting Information,
Data S1.
In addition to the SARC-F questionnaire, we examined clin-
ically relevant factors associated with the outcome of the
5-CST available from the interview with respondent. These
were self-reported long-term conditions, based on a count
of conditions from the following list: hypertension, low blood
pressure, diabetes, stroke, angina, heart attack, cancer,
chronic bronchitis, asthma, hearing impairment, vision im-
pairment, Parkinson’s disease, epilepsy, arthritis, peptic ulcer,
pernicious anaemia, and thyroid problems. We considered
those with two or more to have multimorbidity. Depression
was assessed in CFAS II using the geriatric mental state exam-
ination and the automated geriatric examination for
computer-assisted taxonomy algorithm, with neurosis and
psychosis types of depression being included.16 We catego-
rized the Mini-Mental State Examination as 26–30 (normal),
22–25 (mild impairment), and 21 or below (severe impair-
ment). We considered those who did not complete a
Mini-Mental State Examination but who had a diagnosis of
dementia (from the automated geriatric examination for
computer-assisted taxonomy algorithm12,16) to have severe
impairment for the purpose of analyses. Smoking history
was recorded as current, previous, or never. Participants
were asked a series of questions about different types of ha-
bitual physical activity as developed for use in the English
Longitudinal Study of Ageing17,18 and categorized by their
highest level of activity performed regularly (at least once a
month): vigorous (such a running or heavy gardening), mod-
erate (such as heavy housework or walking at a moderate
pace), and light (such as light housework) or no regular activ-
ity. Place of residence was categorized as living alone, living at
home with others, or living in a care home.
We also classified their socio-economic status using the
Registrar General’s Social Classification into six groups: I, II,
IIINM, IIIM, IV, and V. We grouped participants’ number of
years of full-time education into 0–9, 10–11, and 12+.
Statistical analyses
We restricted the sample to participants of the first wave of
CFAS II with a result for the 5-CST (including those who were
unable to complete the test), the SARC-F questionnaire, and
the clinically relevant factors, as shown in Data S4. We exam-
ined the characteristics of the sample by sex, testing for dif-
ferences using the χ2 test for categorical variables and the
t-test for continuous variables. We described the prevalence
of 5-CST categories by 5 year age and sex groups, grouping
those aged 90+ together. We examined the prevalence of
5-CST categories by the score from the SARC-F questionnaire.
We calculated the sensitivity and specificity of the previously
proposed cut-point of a SARC-F score of 4 or more for poor
performance in the 5-CST.
We investigated other factors associated with the different
categories of the 5-CST. To model the full range of categories,
and because we anticipated that these factors might have
non-proportional effects between each pairs of categories,
we used multinomial logistic regression models with chair
stand category as the outcome variable. We firstly checked
that each factor had a statistically significant association with
the outcome in a model adjusted for age category and sex
only (as shown in Data S2). We then ran a model including
all factors to test which of them had independent associa-
tions with the outcome. In sensitivity analyses, we repeated
the models, excluding (i) those with a SARC-F score of 4 or
above and (ii) those who lived in care homes.
Finally, we described the prevalence of categories of gait
speed among those with poor performance in the 5-CST. All
tests of means and proportions, and all multivariable models
incorporated sampling weights to account for the CFAS II de-
sign and initial non-response.12 We performed all analyses
using Stata Version 14.019 (StataCorp, College Station,
Texas, USA).
Literature search
We searched the MEDLINE database in October 2019 for ar-
ticles relating to the protocol used to perform the 5-CST (also
referred to as the chair rise or sit-to-stand test). For details of
the search terms and number of articles retrieved, please see
Data S3. Two authors (A. G. and C. H.) screened the search
for relevant articles, and a third author (J. M.) summarized
their findings. We used the findings from CFAS II and the lit-
erature search to propose a protocol for the 5-CST.
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Results
Characteristics of the study population
Of the 7796 participants in the first wave of CFAS II, 7303
(93.7%) had a time for the 5-CST or were unable to complete
the test, and 7190 (92.2%) also had data on clinical factors (as
shown in Data S4). Participants with missing data tended to
be older (mean age with missing data 80 and 75 without,
P < 0.001) and more likely to be women (58.5% with missing
data and 54.1% without, P = 0.041).
Women (54.1% of the sample) were on average older
than the men, more likely to have multimorbidity, depres-
sion, cognitive impairment, to undertake light or no physi-
cal activity, to live alone, to have a SARC-F score of 4 or
more, to have fewer than 10 years in full-time education,
Table 1 Characteristics of the sample, by sex
Characteristic [n (%) unless shown otherwise] Male (n = 3297) Female (n = 3893) P-valuea
Age (years), mean (SD) 74.7 (6.69) 75.8 (7.22) <0.001
Age group <0.001
65–69 925 (28.06) 936 (24.04)
70–74 850 (25.78) 928 (23.84)
75–79 716 (21.72) 818 (21.01)
80–84 560 (16.99) 777 (19.96)
85–89 177 (5.37) 279 (7.17)
90+ 69 (2.09) 155 (3.98)
Number of long-term conditions <0.001
0 295 (8.95) 238 (6.11)
1 607 (18.41) 613 (15.75)
2+ 2395 (72.64) 3042 (78.14)
Depression 148 (4.49) 334 (8.58) <0.001
Cognition (MMSE) <0.001
Normal (26–30) 2639 (80.04) 2873 (73.80)
Mild impairment (22–25) 478 (14.50) 744 (19.11)
Severe impairment (≤21) 180 (5.46) 276 (7.09)
Smoking history <0.001
Never smoker 885 (26.84) 1881 (48.32)
Previous smoker 2024 (61.39) 1622 (41.66)
Current smoker 388 (11.77) 390 (10.02)
Physical activity <0.001
Vigorous 1396 (42.34) 930 (23.89)
Moderate 1362 (41.31) 1940 (49.83)
Light/none 539 (16.35) 1023 (26.28)
Place of residence <0.001
Living alone 780 (23.66) 1853 (47.60)
Living at home with others 2493 (75.61) 1989 (51.09)
Living in a care home 24 (0.73) 51 (1.31)
SARC-F score <0.001
0 1875 (56.87) 1309 (33.62)
1 488 (14.80) 732 (18.80)
2 289 (8.77) 551 (14.15)
3 186 (5.64) 396 (10.17)
4+ 459 (13.92) 905 (23.25)
5-CST category <0.001
Fast (<12 s) 1048 (31.79) 865 (22.22)
Intermediate (12–15 s) 747 (22.66) 797 (20.47)
Slow (>15 s) 725 (21.99) 1001 (25.71)
Unable 777 (23.57) 1230 (31.60)
5-CST time (s), mean (SD)b 14.2 (5.72) 15.4 (5.92) <0.001
Years in full-time education (n = 7147) 0.008
0–9 785 (23.98) 1053 (27.19)
10–11 1744 (53.27) 1970 (50.86)
12+ 745 (22.76) 850 (21.95)
Socio-economic status (n = 6937) <0.001
I 285 (8.73) 65 (1.77)
II 724 (22.17) 796 (21.68)
III (M) 1473 (45.10) 502 (13.67)
III (NM) 410 (12.55) 1395 (38.00)
IV 271 (8.30) 687 (18.71)
V 103 (3.15) 226 (6.16)
5-CST, 5-chair stand test; MMSE, Mini-Mental State Examination; SD, standard deviation.
aP-values obtained from appropriate tests using sampling weights.
bAmong those able to complete five chair stands.
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FIGURE 1 Categories of the 5-chair stand test and mean time taken by age and sex. SD, standard deviation.
FIGURE 2 Categories of the 5-chair stand test and mean time taken, by SARC-F score. SD, standard deviation.
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and to be of lower socio-economic status, whereas men
were more likely to be previous or current smokers, as
shown in Table 1.
The chair stand test in relation to age, sex, and
SARC-F score
Average performance in the 5-CST worsened with age, with
poor performance (defined as needing more than 15 s or be-
ing unable to complete the test) present in 34.3% of those
aged 65–69, increasing to 89.7% of those aged 90+, with a
particular increase in the proportion of those unable to com-
plete the test at older ages as shown in Figure 1. Women had
worse performance than men, and this became more obvious
with increasing age (P < 0.01 from a test of age–sex interac-
tion for poor performance).
Performance in the 5-CST worsened with increasing
SARC-F score, as shown in Figure 2. A SARC-F score of 4
or more (the cut-point recommended for the identification
of sarcopenia) was seen in 1364 (19.0%) participants. This
cut-point identified a group with severely impaired chair
stand performance, with 83.0% unable to complete the test
and 13.2% completing it with a slow time. There was
reflected in a high specificity (98.7%) and low sensitivity
(33.2%) of a SARC-F score of 4 or more for poor perfor-
mance in the 5-CST.
The associations of the chair stand test with clinical
factors
In multinomial logistic regression models adjusted for age and
sex, all of the clinical factors tested (multimorbidity, depres-
sion, impaired cognition, current smoking, physical inactivity,
living alone or in a care home, and raised SARC-F score) were
significantly associated with worse performance in the 5-CST
as shown in Data S2. In the multivariable model, all factors
had an attenuated but still significant association with the
5-CST (Table 2).
Table 2 provides odds ratios in which clinical factors (e.g.
multimorbidity) are stratified, and then the odds ratio of be-
ing in a particular 5-CST performance group (as opposed to
having intermediate performance) is compared between
those with the presence or absence of the clinical factor
shown. For example, compared with those without
multimorbidity, those with multimorbidity had a 12% [95%
confidence interval (CI): 2–22%] lower odds of fast 5-CST per-
formance, a 23% (95% CI: 8–40%) higher odds of slower 5-CST
performance, and a 23% (95% CI: 4–45%) higher odds of be-
ing unable to complete the 5-CST. The highest odds ratios for
poor performance were seen for one or more positive re-
sponses to the SARC-F questionnaire, notably for being un-
able to complete the test. In sensitivity analyses, exclusion
of those participants living in care homes and those with a
SARC-F score of 4 or more did not substantially alter the
findings.
Table 2 Multivariable multinomial logistic regression model for 5-chair stand test category
Clinical factor
Odds ratioa [95% CI] compared with intermediate 5-CST
P-valuebFast 5-CST Slow 5-CST Unable to do 5-CST
Multimorbidity: present 0.88 [0.78, 0.98] 1.23 [1.08, 1.40] 1.23 [1.04, 1.45] <0.001
Depression: present 1.25 [0.96, 1.64] 1.54 [1.20, 1.98] 1.24 [0.94, 1.63] 0.004
MMSE category (reference: normal) <0.001
Mild impairment 0.93 [0.79, 1.09] 1.07 [0.92, 1.24] 1.34 [1.13, 1.59]
Severe impairment 0.86 [0.60, 1.24] 1.71 [1.26, 2.32] 2.97 [2.17, 4.05]
Smoking history (reference: never smoker) <0.001
Past smoker 0.89 [0.80, 1.00] 1.00 [0.89, 1.12] 0.90 [0.79, 1.04]
Current smoker 0.77 [0.64, 0.93] 1.25 [1.03, 1.50] 1.28 [1.03, 1.59]
Physical activity (reference: vigorous) <0.001
Moderate 0.78 [0.70, 0.87] 1.23 [1.09, 1.39] 1.31 [1.11, 1.55]
Light/none 0.72 [0.56, 0.93] 1.79 [1.44, 2.21] 3.52 [2.79, 4.45]
Place of residence (reference: living at home with others) <0.001
Living alone 1.01 [0.90, 1.14] 1.08 [0.96, 1.22] 1.36 [1.18, 1.56]
Living in a care home 0.36 [0.08, 1.76] 1.10 [0.46, 2.62] 1.43 [0.61, 3.36]
SARC-F score (reference: 0) <0.001
1 0.83 [0.72, 0.95] 2.15 [1.87, 2.47] 3.34 [2.73, 4.07]
2 0.56 [0.46, 0.68] 2.77 [2.34, 3.29] 9.97 [8.10, 12.27]
3 0.49 [0.35, 0.70] 5.31 [4.16, 6.77] 23.88 [18.27, 31.22]
4+ 0.79 [0.52, 1.19] 6.57 [4.82, 8.97] 113.66 [82.79, 156.04]
5-CST, 5-chair stand test; CI, confidence interval; MMSE, Mini-Mental State Examination.
Model also includes sex and age category (not shown). N = 7190.
aThe odds ratio of being in a particular 5-CST performance group compared with intermediate performance is tested given the presence or
absence of the clinical factor shown. An odds ratio greater than 1 indicates greater odds of being in 5-CST performance category shown
as opposed to having intermediate performance, compared between the level of the clinical factor shown and the reference level.
bP-value for the significance comparing a multivariable model with and without the clinical factor shown.
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The combination of SARC-F, 5-chair stand test, and
gait speed
Using these population-based empirical data, we developed a
modified version of the EWGSOP2 algorithm (shown in
Figure 3). The earlier finding of a wide range of independent
factors associated with poor performance suggests that clini-
cians should check the 5-CST wherever possible, including
among those with a SARC-F score between 1 and 3.
We saw that approximately two-thirds of those with a
slower chair rise time also had slow gait speed. By compari-
son, approximately half of those who were unable to com-
plete the 5-CST had slow gait speed, and approximately
one-third of those unable to complete the 5-CST were also
unable to complete the gait speed test.
Existing literature regarding the protocol for the
chair stand test
Other versions of the chair stand test include the 10-chair
stand test, which was originally developed to assess patients
with myositis.20 There is also a version based on the maxi-
mum number of stands that a person can complete in 30 s,
with 8% of one sample completing fewer than five stands.21
Of the different versions, the 5-CST has been most commonly
used in research studies22 and is the one recommended in
the EWGSOP2 consensus definition.11
We identified three references with detailed protocols for
the 5-CST.2,23,24 The protocol used by Cesari et al.2 was simi-
lar to that in CFAS II, except that timing stopped when partic-
ipants had sat down for the fifth time, instead of when they
had stood up for the fifth time. We found examples of both
timing until sitting down for the fifth time25–27 and on stand-
ing for the fifth time,23,28,29 with the latter including the pro-
tocol by Guralnik et al. for the Short Physical Performance
Battery.23
The height of the chair used is another aspect of protocol
that is recognized to vary between studies, for example, be-
tween 40 and 46 cm, with evidence that lower chair heights
reduce the likelihood of successfully completing the test.30,31
There is therefore a need to standardize chair height espe-
cially if serial measurements are being considered,1 and a
FIGURE 3 Illustration of findings using modified European Working Group on Sarcopenia in Older People 2 algorithm. MMSE, Mini-Mental State
Examination.
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height of approximately 43 cm has been recommended in the
protocol by Bohannon.24 As in CFAS II, it is recognized that if
using a person’s own chair at home, then the height used will
vary.32 Finally, one study found that a moderately cold envi-
ronment (15°C) reduced the sit-to-stand performance of
women at mean age 78 years compared with a warm/normal
environment (25°C).33 We combined the protocol used in
CFAS II, the findings from our analyses, and the existing liter-
ature to propose a recommended protocol for the use of
5-CST as shown in Figure 4.
Discussion
Summary of findings
We investigated the prevalence and factors associated with
poor performance in the 5-CST in a large representative
sample of older people in three diverse localities of England.
We found that performance declined with age, including an
increasing proportion of those unable to complete the 5-
CST. A SARC-F score of 4 or more was highly specific, but
not sensitive, for poor performance in the 5-CST. A range of
clinically relevant variables including multimorbidity, depres-
sion, impaired cognition, and smoking was also indepen-
dently associated with poor performance. A literature
review revealed variation in the protocol for the 5-CST test,
including the timing and the height of the chair used. We
have used our findings to recommend a protocol for the
use of the 5-CST in the assessment of sarcopenia, applicable
in both clinical and research settings.
Strengths and limitations of the present study
We designed a study to address several clinically relevant
questions regarding the 5-CST, which arise from the
FIGURE 4 Newcastle protocol for assessment of chair stand test in suspected sarcopenia.
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EWGSOP2 sarcopenia consensus definition. We used data
from the CFAS II, a large population-based sample from three
geographical areas from the UK designed to estimate the
prevalence of dementia.12 We had information on the major-
ity (92%) of this sample in terms of 5-CST performance and its
associated factors. Those with missing data (8%) were older
on average and more likely to be female. A limitation of the
present study is that it did not assess body mass index as a
clinical factor, which has been linked to performance in the
5-CST.34 We used a statistical technique (multinomial logistic
regression) that allowed us to incorporate the full range of
5-CST performance in analyses, including those unable to
complete the test, which became increasingly prevalent at
older ages.
Comparison with existing studies
We saw an increase in the average time taken to complete
the 5-CST with increasing age (Figure 1). A previous
meta-analysis of 14 studies of the 5-CST also showed an in-
crease with age but of a lower magnitude than in the present
study, with a pooled time for both women and men of 11.4 s
in those aged 60–69 increasing to 12.7 in those aged 80–8935;
the faster 5-CST times than those seen in our study may re-
flect the inclusion of convenience samples, whereas CFAS II
is a population-based study carried out in three diverse geo-
graphical localities. We also saw a sharp increase with age
in the proportion of participants unable to complete the
CST, rising above 50% in the 85–89 age group. We are not
aware of other studies that have reported the prevalence of
being unable to complete the 5-CST by age group, although
previous work suggests that the likelihood of being unable
to complete the 5-CST5 and a single chair stand36 increases
with age.
A higher SARC-F score was also associated with worse per-
formance in the 5-CST (Figure 2 and Table 2). A SARC-F score
of 4 or more had high specificity but low sensitivity for poor
performance in the 5-CST, as described previously in relation
to sarcopenia in general.37,38 This highlights the need for
other ways to identify people likely to have probable
sarcopenia, referred to as clinical suspicion in the EWGSOP2
guidance.11 We have previously showed that multimorbidity,
any positive SARC-F responses, polypharmacy, lower body os-
teoarthritis, and physical inactivity were factors associated
with probable sarcopenia at age 69.39,40 In the present study,
we found that impaired cognition, current smoking, and living
in a care home were also associated with poor performance.
From a literature review, we found that the 5-CST has been
widely applied and is the most commonly used type of chair
stand test. The 5-CST also forms part of the short physical
performance battery, in combination with the standing bal-
ance and gait speed tests.23 We found variation in the proto-
col used, in terms of chair height and the point at which
timing is stopped, both of which have the potential to affect
the result obtained. We proposed a protocol to facilitate the
use of the 5-CST in the context of suspected sarcopenia
(Figure 4).
Implications for clinical practice and future
research
The EWGSOP2 definition recommends the use of grip
strength or the 5-CST to identify patients with probable
sarcopenia. Our findings highlight that with increasing age,
there is a sharp increase in the proportion of individuals
who are unable to complete the test. There is evidence
that this proportion is even greater among medical
inpatients.41 In contrast, grip strength is feasible both in
the very old and among inpatients.42,43 We also saw that
the majority of those with poor performance in the 5-CST
also had poor performance in the gait speed test. Poor per-
formance in the 5-CST, especially non-completion, may
therefore highlight individuals who would be categorized
as having severe sarcopenia according the EWGSOP2 defini-
tion and hence should be prioritized for further assess-
ment. Performance in the 5-CST has also been shown to
depend on sensation and balance, and hence, poor perfor-
mance in the 5-CST should also prompt clinical assessment
of these factors.44
We found that participants who were unable to com-
plete the 5-CST had a range of adverse health and lifestyle
factors including functional impairment on the SARC-F
questionnaire, multimorbidity, impaired cognition, low
mood, current smoking, and low physical activity. Being un-
able to complete the 5-CST has also been linked to hip
fracture5 and increased all-cause mortality rates.13 This all
suggests that as well as an indication to carry out further
assessment of sarcopenia, being unable to complete the
5-CST is an indication to undertake a comprehensive geriat-
ric assessment such as recommended for older adults living
with frailty.45 Our findings also highlight that capturing non-
completion of the 5-CST, and the reasons for it, is impor-
tant in research studies related to sarcopenia. This is espe-
cially relevant in clinical trials where individuals may
become unable to complete the 5-CST during follow-up,
as also recognized when using physical performance mea-
sures in trials of frailty prevention.46
Conclusions
Poor performance (being slow or unable) in the 5-CST is al-
ready prevalent at age 65–69, with approximately one-third
affected, and becomes increasingly common at older ages.
A wide range of independent factors including any positive
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SARC-F responses, multimorbidity, depression, and impaired
cognition identify individuals who are likely to have poor per-
formance, suggesting that clinicians should have a low
threshold for attempting the test. We have proposed a proto-
col for the 5-CST, which should facilitate its use in the assess-
ment of suspected sarcopenia.
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